| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-913 | |
| Phytochemical name or plant extracts | Broussoflavonol B | |
| PMID | 23769740 | |
| Literature evidence | Here, we report that Broussoflavonol B, a chemical purified from the bark of the Paper Mulberry tree (Broussonetia papyrifera) exhibited potent growth inhibitory activity in ER-negative breast cancer MDA-MB-231 cells at sub-micromolar concentrations. | |
| IUPAC name | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-6,8-bis(3-methylbut-2-enyl)chromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavonoids | |
| Source of phytochemicals or plant Extracts | Broussonetia papyrifera | |
| Geographical availability | Assam, Bangladesh, Cambodia, China North-Central, China South-Central, China Southeast, Hainan, India, Korea, Laos, Myanmar, Taiwan, Thailand, Tibet, Vietnam | |
| Plant parts | Bark | |
| Other cancers | Breast cancer | |
| Target gene or protein | c-Myc , p16(INK4a), p19(INK4D), p21(WAF1/CIP1), Cyclin B1, cdc2, cdc25C, ER-α36, Epidermal growth factor receptor | |
| Gene or Protein evidence | Broussoflavonol B induced cell cycle arrest at both the G₀/G₁ and G₂/M phases accompanied by a downregulation of c-Myc protein, a upregulation of the cell cycle inhibitory proteins p16(INK4a), p19(INK4D) and p21(WAF1/CIP1) and a down-regulation of the expression levels of the G₂/M regulatory proteins such as cyclin B1, cdc2 and cdc25C. In addition, Broussoflavonol B treatment also decreased the steady state levels of the epidermal growth factor receptor (EGFR) and ER-α36, a variant of estrogen receptor-α, and restricted growth of the stem-like cells in ER-negative breast cancer MDA-MB-231 cells. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | In addition, Broussoflavonol B treatment also decreased the steady state levels of the epidermal growth factor receptor (EGFR) and ER-α36, a variant of estrogen receptor-α, and restricted growth of the stem-like cells in ER-negative breast cancer MDA-MB-231 cells. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | Our results thus indicate that Broussoflavonol B is a potent growth inhibitor for ER-negative breast cancer cells and provide a rational for preclinical and clinical evaluation of Broussoflavonol B for ER-negative breast cancer therapy. | |
| PubChem ID | 480828 | |
| Additional PMIDs | 23645733 23769740 32429421 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:850861-1 | |
| Safety | NA |